Pathology Department, Memorial Sloan-Kettering Cancer Center, New York, NY; Pathology Department, Institut Bergonié Cancer Center, Bordeaux, France.
Genes Chromosomes Cancer. 2014 Jun;53(6):475-86. doi: 10.1002/gcc.22159. Epub 2014 Mar 3.
Epithelioid sarcomas (ES) are mesenchymal neoplasms subclassified into distal and proximal subtypes based on their distinct clinical presentations and histologic features. Consistent loss of SMARCB1 nuclear expression has been considered as the hallmark abnormality for both subtypes, a feature shared with atypical teratoid/rhabdoid tumor of infancy (ATRT). While virtually all ATRTs harbor underlying SMARCB1 somatic or germline alterations, mechanisms of SMARCB1 inactivation in ES are less well defined. To further define mechanisms of SMARCB1 inactivation a detailed molecular analysis was performed on 40 ES (25 proximal and 15 distal ES, with classic morphology and negative SMARCB1 expression) for their genomic status of SMARCB1 and related genes encoding the SWI/SNF subunits (PBRM1, BRG1, BRM, SMARCC1/2 and ARID1A) by FISH using custom BAC probes. An additional control group was included spanning a variety of 41 soft tissue neoplasms with either rhabdoid/epithelioid features or selected histotypes previously shown to lack SMARCB1 by IHC. Furthermore, 12 ES were studied by array CGH (aCGH) and an independent TMA containing 50 additional ES cases was screened for Aurora Kinase A (AURKA) and cyclin D1 immunoexpression. Homozygous SMARCB1 deletions were found by FISH in 36/40 ES (21/25 proximal-type). One of the distal-type ES displayed homozygous SMARCB1 deletion in the tumor cells, along with a heterozygous deletion within normal tissue, finding confirmed by array CGH. None of the proximal ES lacking homozygous SMARCB1 deletions displayed alterations in other SWI/SNF subunits gene members. Among controls, only the SMARCB1-immunonegative myoepithelial carcinomas displayed SMARCB1 homozygous deletions in 3/5 cases, while no gene specific abnormalities were seen among all other histologic subtypes of sarcomas tested regardless of the SMARCB1 protein status. There was no consistent pattern of AURKA and Cyclin D1 expression. The array CGH was successful in 9/12 ES, confirming the SMARCB1 and other SWI/SNF genes copy numbers detected by FISH. Our study confirms the shared pathogenesis of proximal and distal ES, showing consistent SMARCB1 homozygous deletions. Additionally we report the first ES case associated with a SMARCB1 constitutional deletion, establishing a previously undocumented link with ATRT. Alternative mechanisms of SMARCB1 inactivation in SMARCB1-disomic ES remain to be identified, but appear unrelated to large genomic abnormalities in other SWI/SNF subunits.
上皮样肉瘤(ES)是一种间叶性肿瘤,根据其不同的临床表现和组织学特征,分为远端和近端亚型。一致的 SMARCB1 核表达缺失被认为是两种亚型的标志性异常,这一特征与婴儿型非典型畸胎瘤/横纹肌样瘤(ATRT)共享。虽然几乎所有的 ATRT 都存在潜在的 SMARCB1 体细胞或种系改变,但 ES 中 SMARCB1 失活的机制还不太清楚。为了进一步明确 SMARCB1 失活的机制,对 40 例 ES(25 例为近端 ES,15 例为远端 ES,具有典型形态且 SMARCB1 表达阴性)进行了详细的分子分析,使用定制的 BAC 探针通过 FISH 检测其 SMARCB1 和编码 SWI/SNF 亚基(PBRM1、BRG1、BRM、SMARCC1/2 和 ARID1A)的相关基因的基因组状态。此外,还包括一组 41 种软组织肿瘤作为对照,这些肿瘤具有横纹肌样/上皮样特征或通过免疫组化显示缺乏 SMARCB1 的特定组织学类型。进一步,对 12 例 ES 进行了 array CGH(aCGH)分析,并对包含 50 例额外 ES 病例的独立 TMA 进行了 Aurora Kinase A(AURKA)和 cyclin D1 免疫组化检测。在 40 例 ES 中,通过 FISH 发现 36 例(21 例为近端型)存在 SMARCB1 纯合缺失。1 例远端型 ES 肿瘤细胞中存在 SMARCB1 纯合缺失,正常组织中存在杂合缺失,通过 array CGH 得到证实。在没有 SMARCB1 纯合缺失的近端 ES 中,没有发现其他 SWI/SNF 亚基基因成员的改变。在对照组中,只有 3/5 例 SMARCB1 免疫阴性的肌上皮癌显示 SMARCB1 纯合缺失,而在所测试的所有其他肉瘤组织学亚型中,无论 SMARCB1 蛋白状态如何,均未发现其他基因特异性异常。AURKA 和 cyclin D1 的表达没有一致的模式。aCGH 在 9/12 例 ES 中获得成功,证实了 FISH 检测到的 SMARCB1 和其他 SWI/SNF 基因的拷贝数。我们的研究证实了近端和远端 ES 的共同发病机制,显示出一致的 SMARCB1 纯合缺失。此外,我们报告了首例与 SMARCB1 结构缺失相关的 ES 病例,与 ATRT 建立了以前未记录的联系。在 SMARCB1 二倍体 ES 中,SMARCB1 失活的其他机制仍有待确定,但与其他 SWI/SNF 亚基的大基因组异常无关。